



## **POLICY ON CONDUCTING CLINICAL RESEARCH STUDIES IN OASAS-CERTIFIED, FUNDED, OR OTHERWISE AUTHORIZED PROGRAMS**

### **PURPOSE**

This policy addresses conducting clinical research studies with medications or medical devices in OASAS- certified, funded, or otherwise authorized programs (“OASAS programs”).

### **POLICY**

OASAS receives requests from medical professionals, companies, and corporations seeking to conduct clinical research studies involving medications and medical devices in OASAS programs. To support such research in OASAS programs, the medications or medical devices must be used for an indication that has been approved by the Food and Drug Administration (FDA). The use of medications or medical devices for non-indicated or “off- label” reasons in clinical research studies in OASAS programs will be permitted only if their use is in conjunction with a federally funded research grant and also will be assessed by OASAS on a case-by-case basis in conjunction with New York State law. Medical professionals, companies, or corporations making such requests of OASAS programs should be directed to contact an appropriate national research organization such as the National Institute on Drug Abuse (NIDA), the National Institutes of Health (NIH), or the National Institute of Mental Health (NIMH) for assistance in pursuing research on novel medical therapies.

Questions about this policy or requests to conduct clinical research in OASAS programs can be sent to the Addiction Medicine Mailbox: [OASAS.sm.AddictionMedicine](mailto:OASAS.sm.AddictionMedicine).

Posted 1/24/2023